Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles

HÅKON REIKVAM1,2, ANITA RYNINGEN1,4, LARS RUNE SÆTERDAL3, INA NEPSTAD1, BRYNJAR FOSS3 and ØYSTEIN BRUSERUD1,2

1Institute of Clinical Science, University of Bergen; 2Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen; 3Department of Health Studies, University of Stavanger, Stravanger; 4Department of Biomedical Laboratory Sciences and Chemical Engineering, Bergen University College, Bergen, Norway

Received October 2, 2014; Accepted December 17, 2014

DOI: 10.3892/ijmm.2014.2045

Abstract. Bone marrow stromal cells support both normal and malignant hematopoiesis. This support is mediated through the local cytokine network and by direct cell-cell interactions mediated via adhesion molecules and the formation of gap junctions by connexins. Previous studies on connexins in human acute myeloid leukemia (AML) have mainly focused on the investigation of leukemia cell lines. In the present study, we therefore investigated the expression of various connexins at the protein (i.e., cell surface expression) and mRNA level in primary human AML cells. The cell surface expression of the connexins, Cx26, Cx32, Cx37, Cx43 and Cx45, varied considerably between patients, and detectable levels were observed only for subsets of patients. On the whole, Cx43 and Cx45 showed the highest cell surface expression. Connexin expression was dependent on AML cell differentiation, but showed no association with cytogenetic abnormalities or mutations of the fms-related tyrosine kinase 3 (FLT3) or nucleophosmin (NPM)-1 genes. By contrast, only Cx45 showed a significant variation between patients at the mRNA level. A high Cx45 expression was associated with the altered regulation of the mitogen-activated protein kinase (MAPK) pathway and the release of pro-inflammatory cytokines [interleukin (IL)-17, tumor necrosis factor (TNF), interferon-γ], whereas a low Cx45 expression was associated with the altered regulation of protein functions (i.e., ligase activity, protein folding and catabolism). There was no significant correlation observed between the connexin mRNA and protein levels. Thus, differences in connexin expression can be used to subclassify AML patients. Differences in connexin cell surface expression profiles are not reflected at the mRNA level and have to be directly examined, whereas variations in Cx45 mRNA expression are associated with differences in cell signaling and the regulation of protein functions.

Introduction

Bone marrow stromal cells (e.g., fibroblasts, osteoblasts, endothelial cells) support both normal and leukemic hematopoiesis (1). This support is mediated both via the local cytokine network and by direct cell-cell contact, including gap junctions formed by connexin molecules (2). This also seems to be true in acute myeloid leukemia (AML), an aggressive myeloid malignancy characterised by the accumulation of immature forms of leukemic blasts in the bone marrow (3). Stromal cells seem to be important both for leukaemogenesis and chemosensitivity (1). This is supported by in vitro studies on exogenous cytokines known to be released by stromal cells (4-6) and by the in vitro co-culture of primary human AML cells with human fibroblasts (7), endothelial cells (8) and osteoblasts (9). Murine stromal cells (10) also have growth-enhancing and anti-apoptotic effects on primary human AML cells.

Gap junctions and connexins play an important role in AML (11), and the differentiation of the AML cell lines, HL-60 and PBL-985, is inhibited by stromal cells; this effect is possibly mediated by gap junctions (12). However, the results from studies on the effects of gap junctions on AML cell proliferation are conflicting. Firstly, gap junctions seem to exert antiproliferative effects on the HL-60 and KG1 AML cell lines (13). An antiproliferative effect has also been observed in the U937 AML cell line when increased Cx43 mRNA levels are induced by the expression of the AML1-ETO fusion gene; however, it is not known whether this antiproliferative effect is caused by the induction of Cx43 or by another effect of the fusion protein (14). If this antiproliferative effect, which is associated with increased Cx43 expression, is caused by Cx43 itself and not by another effect of the AML-ETO fusion protein, this may be associated with human AML, as increased Cx43 gap junction expression has also been detected in human AML bone marrow biopsies (15). By contrast, an in vitro study demonstrated a higher proliferative capacity of the OCIM2...
AML cells with increased Cx43 expression compared with cells showing a considerably lower Cx43 expression (16). Finally, antileukemic chemotherapy has been shown to reduce Cx43 expression in normal hematopoietic cells as bone marrow levels are reduced following intensive chemotherapy compared with both AML marrow and marrow from healthy controls; however, it remains unknown as to whether chemotherapy has a similar effect on Cx43 expression in primary AML cells and whether this is a determining factor for the antileukemic effectiveness of the treatment (17). Taken together, these observations suggest that gap junctions and connexins are involved in leukemogenesis and are important for chemosensitivity. However, many of these studies are mainly based on the use of AML cell lines. Thus, in the present study, we investigated the expression of connexins in well-characterised primary human AML cells derived from unsel ected patients.

Materials and methods

Patients and cell preparation. This study was approved by the local ethics committee (Regional Ethics Committee III, University of Bergen, Bergen, Norway), and the samples were collected after obtaining written informed consent from all participants. AML blasts were derived from consecutive and thereby unsel ected patients with high peripheral blood blast counts (18). This selection of patients together with the analysis of fms-related tyrosine kinase 3 (FLT3) and nucleophosmin (NPM)-1 mutations has been described previously (18,19). The expression of molecular markers for myeloid differentiation was analysed by flow cytometry, as previously described (20). We investigated connexin protein expression in 38 patients (referred to as cohort 1) and gene expression profiling (GEP) in a second group of 48 patients (cohort 2). This cohort was comparable with cohort 1 and included consecutive patients with relatively high peripheral blood blast counts. The clinical and biological characteristics of the two cohorts are presented in Table I.

Preparation of AML cells. The leukemic cells were isolated by density gradient separation (Ficoll-Hyapaque; specific density, 1.077; Nycomed Pharma, Oslo, Norway), and were stored frozen in liquid nitrogen (4,6,7,21). Leukemia peripheral blood mononuclear cells were collected from the AML patients with >95% of leukemic blasts among the mononuclear cells.

Flow cytometry. Flow cytometric analysis to assess cell surface molecular expression was carried out as described in our previous study (7). Briefly, 1x10⁵ AML cells/ml were washed once in binding buffer [phosphate buffered saline (PBS) with 0.2% bovine serum albumin (BSA)] prior to incubation in the dark for 20 min at room temperature with FITC-conjugated antibodies against Cx26 (sc-7261), Cx32 (sc-7258), Cx37 (sc-27712), Cx43 (sc-13558) or Cx45 (sc-374354; Santa Cruz Biotechnology, Inc., CA, USA). The samples were then washed once before flow cytometric analysis. For each measurement, 10,000 events were collected using a standard FACSCalibur flow cytometer (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) equipped with an Argon laser (488 nm) and a red diode laser (635 nm). A cytogram based on the forward angle light scatter (FSC) versus the right angle side scatter (SSC) was used to eliminate aggregates, debris and dead cells before fluorescence was detected. In the analysis of connexin membrane expression, only green fluorescence (FL1) was detected through the 530-540 nm band-pass filter. The fluorescence measurements were collected in the logarithmic mode. Both data from the positive cell region diagrams and the mean fluorescence intensity (MFI) were analysed using FCS Express version 3 (De Novo Software, Los Angeles, CA, USA). The positive cell regions were defined for each individual patient based on the FSC/SSC diagrams and contained <2% and >1% of the cells of the unstained negative controls.

Microarray analysis. Global gene expression analyses were performed for a second patient cohort (Table I). We then used

| Patient characteristics (consecutive patients in both cohorts) | Cohort 1 (cell surface expression) | Cohort 2 (gene expression profiles) |
|---------------------------------------------------------------|------------------------------------|-------------------------------------|
| Demographic data and disease history                          |                                    |                                     |
| Gender (no.)                                                  |                                    |                                     |
| Male/female                                                   | 17/21                              | 23/25                               |
| Age                                                          |                                    |                                     |
| Median (range)                                                | 63.4 (29-88)                       | 60.5 (24-84)                        |
| History                                                       |                                    |                                     |
| De novo                                                       | 24 (63%)                           | 40 (83%)                            |
| Secondary                                                     | 8 (21%)                            | 4 (8%)                              |
| Relapse                                                       | 6 (16%)                            | 4 (8%)                              |
| AML cell differentiation                                      |                                    |                                     |
| FAB classification                                            |                                    |                                     |
| M0-1                                                          | 9 (24%)                            | 16 (33%)                            |
| M2                                                            | 9 (24%)                            | 10 (21%)                            |
| M3                                                            | 1 (3%)                             | 0 (0%)                              |
| M4-5                                                          | 19 (50%)                           | 22 (46%)                            |
| CD34 expression expression                                    |                                    |                                     |
| 0-20%                                                         | 16 (42%)                           | 15 (36%)                            |
| 20-50%                                                        | 5 (13%)                            | 5 (12%)                             |
| 50-100%                                                       | 17 (45%)                           | 22 (52%)                            |
| Genetic abnormalities                                         |                                    |                                     |
| Cytogenetics                                                  |                                    |                                     |
| Favourable                                                    | 3 (9%)                             | 2 (4%)                              |
| Intermediate                                                  | 2 (6%)                             | 2 (4%)                              |
| Adverse                                                      | 8 (24%)                            | 10 (21%)                            |
| Normal                                                        | 10 (30%)                           | 25 (52%)                            |
| Not available                                                 | 10 (30%)                           | 9 (19%)                             |
| FLT3 mutations                                                | 15 (44%)                           | 21 (44%)                            |
| NPM-I mutations                                               | 12 (32%)                           | 17 (35%)                            |

AML, acute myeloid leukemia.
Primary human AML cells differ in their cell surface connexin expression. The surface membrane expression of Cx32, Cx37, Cx43 and Cx45 was analysed for primary human AML blasts derived from 38 consecutive unselected patients; Cx26 was only analysed for 16 unselected patients. The results from flow cytometry were analysed both with regard to the percentages of positively stained cells and the MFI. The expression of all the connexins examined varied between patients (Fig. 1). The highest surface expression was observed for Cx45; 55% of the patients (21/38) had at least 20% Cx45-positive cells, whereas the fraction of patients showing at least 20% positive cells was lower for Cx43 (16/38, 42%), Cx37 (13/38, 34%), Cx32 (5/38, 13%) and Cx26 (5/16, 31%). The MFI values for Cx32, Cx37, Cx43 and Cx45 showed statistically significant correlations with each other (all p<0.001, Table II). The strongest correlation was observed between Cx43 and Cx45 expression (Spearman's correlation, ρ=0.930), and a strong linear correlation was also suggested by regression analysis (R²=0.896).

Connexin cell surface expression is associated with the expression of myeloid differentiation markers (CD11c, CD13, CD14, CD15), but not with the expression of the CD34 stem cell marker. The correlations between the cell surface expression of connexins (Cx32, Cx37, Cx43, Cx45) and the myeloid differentiation markers, CD11c, CD13, CD14, CD15 and CD33, as well as the stem cell marker, CD34, were then analysed (Table III). All four connexins showed inverse correlations with CD13 expression (p<0.05 for all), but only Cx43 and Cx45 showed additional positive correlations with CD14 and CD15 expression (p<0.05). Furthermore, Cx45 expression positively correlated with CD11c expression (p=0.037), whereas none of the connexins showed significant correlations with CD33 or CD34 expression (Table III).

Connexin expression correlates with the morphological signs of differentiation, but not with cytogenetic abnormalities,
and FLT3 and NPM-1 mutations. All patients analysed for connexin cell surface expression were classified according to the FAB criteria and this morphological/histochemical classification was used to group the patients into two major subsets as follows: i) AML cells showing no or minimal signs of differentiation (FAB classification M0, M1 and M2); and ii) signs of monocytic differentiation (FAB M4 and M5) (Fig. 2). The expression of Cx32 and Cx35 did not differ between the two subsets (data not shown), whereas Cx43 and Cx45 expression was significantly increased in the AML cells with monocytic differentiation (Fig. 2; p=0.0111 and p=0.0054, respectively, Mann-Whitney U test). There were no differences observed in connexin expression when comparing patients with different cytogenetic abnormalities and patients with or without FLT3/NPM-1 mutations (data not shown).

Hierarchical clustering identifies a subset of patients with a generally low cell surface connexin expression. An unsupervised hierarchical clustering was performed based on the expression of Cx32, Cx37, Cx43 and Cx45 in AML cells. This analysis was based on the percentages of positively stained cells, and the use of the complete linkage method and the Euclidean distance (Fig. 3). Cx32 and Cx37 were clustered together, and Cx43 was clustered with Cx45. The three clusters did not differ with regard to cytogenetic abnormalities, FLT3 or NPM-1 mutations (data not shown), and no significant differences were observed in FAB classification between the clusters either (Fig. 3).

We performed an additional hierarchical clustering analysis (complete linkage method and Euclidean distance) based on the expression of connexins and the cell surface differentiation markers, CD11c, CD13, CD14, CD15 and CD33 (Fig. 4). The two pairs of connexins (Cx32/Cx37 and Cx43/Cx45) clustered...
closely together in this analysis as well; CD14 clustered close to Cx32/Cx37, whereas CD15 clustered close to Cx43/Cx45. The majority of patients with a high Cx43/Cx45 expression formed a separate cluster (8 patients, lower section of heatmap).

Only Cx45 expression shows a wide variation between patients at the mRNA level and differences in Cx45 mRNA levels are associated with distinct gene expression profiles. We used the microarray data obtained from a second cohort of AML patients (cohort 2, Table I). This cohort was comparable with cohort 1 and included consecutive patients with relatively high peripheral blood blast counts (see Materials and methods) (Table I). Among the connexins investigated, Cx45 (encoded by the GJC1 gene) was the only one that showed a relatively high expression and a wide variation in expression between patients, whereas the other connexins showed relatively low mRNA levels and only minor variation in expression between patients. Thus, the relatively wide variation in expression between patients with regard to the connexin...
protein expression profile is not reflected in the mRNA expression profile, an observation suggesting that transcriptional regulation is important for the expression of several connexins.

We then used gene set enrichment analysis (GSEA) to compare the global gene expression profiles for two contrasting patient subsets; the first subset included 15 AML patients with the highest GJC1 expression (GJC1 high) and the second included 15 patients with the lowest GJC1 expression (GJC1 low). Using the leading genes belonging to the top ten gene ontology (GO) terms enriched in both the low and high groups, we were able to 225 genes enriched in at least one GO term. These genes were used to perform a hierarchical clustering analysis, dividing the two groups in two distinct clusters, except one outlier. The heatmap shows downregulated genes (green) and upregulated genes (red); the GO terms in which the marked genes belonged to are in the bottom of the figure.

Figure 5. Hierarchical clustering based on gene set enrichment analysis for patients with a high Cx45 mRNA expression. We used global gene expression analyses of the acute myeloid leukemia (AML) cells for 48 consecutive patients (cohort 2), and we compared the 15 patients with highest GJC1 expression (red column bar) and the 15 patients with the lowest GJC1 expression (green column bar). We performed a gene set enrichment analysis (GSEA), comparing the two distinct groups. By using the leading genes belonging to the top ten gene ontology (GO) terms enriched in both the low and high groups, we were able to 225 genes enriched in at least one GO term. These genes were used to perform a hierarchical clustering analysis, dividing the two groups in two distinct clusters, except one outlier. The heatmap shows downregulated genes (green) and upregulated genes (red); the GO terms in which the marked genes belonged to are in the bottom of the figure.

protein expression profile is not reflected in the mRNA expression profile, an observation suggesting that transcriptional regulation is important for the expression of several connexins.

We then used gene set enrichment analysis (GSEA) to compare the global gene expression profiles for two contrasting patient subsets; the first subset included 15 AML patients with the highest GJC1 expression (GJC1 high) and the second included 15 patients with the lowest GJC1 expression (GJC1 low). Using the leading genes belonging to the top ten gene ontology (GO) terms enriched in both the low and high groups, we were able to 225 genes enriched in at least one GO term. These genes were used to perform a hierarchical clustering analysis, dividing the two groups in two distinct clusters, except one outlier. The heatmap shows downregulated genes (green) and upregulated genes (red); the GO terms in which the marked genes belonged to are in the bottom of the figure.

Discussion

Leukemic hematopoiesis is supported by various stromal cells (1). In human AML, this support seems to be caused both by communication through gap junctions formed by connexins (2), as well as adhesion molecule binding and the stromal release of leukemia-supporting cytokines (7-10). This support may be important both for AML development and chemosensitivity (11). The supportive role of gap junctions/connexins has mainly been studied in AML cell lines. In the present study, we therefore investigated connexin expression in primary human AML cells. Cx43 and Cx45 in particular showed a relatively high cell-surface expression compared with the other connexins examined. These differences between connexins may be caused by several mechanisms, including differences in mRNA expression, post-transcriptional regulation or protein turnover/degradation (24).

Combined data of mRNA and protein expression was available for 19 overlapping patients between cohorts 1 and 2; however, no significant correlations were detected between the mRNA and protein levels for any connexin (data not shown). Thus, patient subclassification based on connexin expression at the mRNA and protein level identifies different subsets, and this is possibly due to post-transcriptional regulation of the protein levels.
able expression levels of Cx32 on the cell surface. The role of Cx32 in leukemogenesis may therefore differ and contribute to the heterogeneity in leukemogenesis between patients (26).

This study demonstrated that all investigated connexins (i.e., Cx26, Cx32, Cx37, Cx43 and Cx45) were expressed in AML cells, but detectable expression for >40% of the patients was observed only for Cx43 (42%) and Cx45 (55%), even though these two connexins showed the lowest mRNA expression. Furthermore, studies on both normal and leukemic bone marrow cells have demonstrated the formation of Cx43 gap junctions between stromal and hematopoietic cells, as well as the upregulation of Cx43 gap junctions in AML marrow (15). Cx43 gap junctions also mediate the communication between normal CD34+ hematopoietic stem cells and stromal cells (27); animal models with the loss of a single Cx43 allele have shown decreased normal hematopoiesis (28), and gene deletion of Cx43 in mice has been shown to decrease hematological recovery following treatment with 5-fluorouracil (29). The present study suggests that Cx43 is also important in leukemic hematopoiesis at least for a subset of patients.

The protein expression of several connexins showed a significant inverse (CD13) or positive correlation (CD11c, CD14, CD15) with molecular differentiation markers, and increased levels were also associated with morphological signs of differentiation. By contrast, connexin protein expression showed no association with cytogenetic abnormalities or mutations of the FLT3 or NPM-1 genes. Taken together, these observations suggest that differentiation is important for connexin expression, whereas NPM-1 or FLT3 mutations only have a minor impact on connexin expression.

Both Cx45 and Cx43 have been linked to stem cell functions and are expressed by human, as well as mouse embryonic stem cells (30-32). In murine cells, they can form heterodimeric gap junction channels (32). Our experiments revealed that Cx43 and Cx45 expression was closely correlated (Fig. 3); however, based on our data, it cannot be concluded whether this correlation represents a molecular basis for the formation of heterodimers.

We observed several significant correlations between the expression of various connexins (Fig. 2), even though the protein expression of Cx26 and Cx32 was very low or absent in the majority of patients, and several patients were negative for Cx37 expression. It is not certain whether Cx37 plays a role in normal or neoplastic hematopoiesis, although its expression has been detected in bone marrow endothelial cells (15), where it is important for monocyte adhesion (33). Cx37 expression may indirectly affect leukemic hematopoiesis through its involvement in AML-associated angiogenesis or interactions with AML cells in the endothelial stem cell niches.

The present study demonstrates that several connexins, Cx43 and Cx45 in particular, are expressed on the surface of primary human AML cells in a large subset of patients. The profile of connexin protein expression can be used for the subclassification of patients. This variation in protein expression cannot be detected at the mRNA level, where only Cx45 expression shows a considerable variation between patients. This Cx45 mRNA variation is also associated with differences in intracellular and extracellular cytokine signaling, as well as the regulation of protein function. These observations suggest that different subsets of patients are identified when the subclassification is based on the protein and mRNA expression of connexins.

References

1. Shiozawa Y, Havens AM, Pienta KJ and Taichman RS: The bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasites. Leukemia 22: 941-950, 2008.
2. Foss B, Hervig T and Bruserud Ø: Connexins are active participants of hematopoietic stem cell regulation. Stem Cells Dev 18: 807-812, 2009.
3. Shipley JL and Butera JN: Acute myelogenous leukemia. Exp Hematol 37: 649-658, 2009.
4. Foss B, Ulvestad E and Bruserud Ø: Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol 66: 365-376, 2001.
5. Bruserud Ø: IL-4, IL-10 and IL-13 in acute myelogenous leukemia. Cytokines Cell Mol Ther 4: 187-198, 1998.
6. Foss B, Mentzoni L and Bruserud Ø: Effects of vascular endothelial growth factor on acute myelogenous leukemia blasts. J Hematother Stem Cell Res 10: 81-93, 2001.
7. Rynningen A, Wergeland L, Glenjen N, Gjertsen BT and Bruserud Ø: In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of pro-angiogenic interleukin 8. Leuk Res 28: 185-196, 2004.
8. Hatfield K, Rynningen A, Corbascio M and Bruserud Ø: Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer 119: 2312-2321, 2006.
9. Bruserud Ø, Rynningen A, Wergeland L, Glenjen N and Gjertsen BT: Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89: 391-402, 2004.
10. Konopleva M, Konoplev S, Hu W, Zaitseks AY, Afanasiev BV and Andreeff M: Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 16: 1713-1724, 2002.
11. Foss B, Transtad KJ and Bruserud Ø: Connexin-based signaling in acute myelogenous leukemia (AML). Biochim Biophys Acta 1798: 1-8, 2010.
12. Weber MC and Tykociński ML: Bone marrow stromal cell blockade of human hematologic cell differentiation. Blood 83: 2221-2229, 1994.
13. Paragauß-Braga FH, Borovicjč R, Bouzais LF, Barcinski MA and Bonomo A: Bone marrow stroma inhibits proliferation and apoptosis in leukemic cells through gap junction-mediated cell-cell communication. Cell Death Differ 10: 1101-1108, 2003.
14. Li X, Xu Y-B, Wang Q, et al: Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML1-ETO-induced growth arrest in leukemic cells. J Cell Physiol 208: 594-601, 2006.
15. Krenacs T and Rosendaal M: Connexin43 gap junctions in normal, regenerating, and cultured mouse bone marrow and in human leukemias: their possible involvement in blood formation. Am J Pathol 152: 993-1004, 1998.
16. Yi S, Chen Y, Wen L, Yang L and Cui G: Expression of connexin 32 and connexin 43 in acute myeloid leukemia and their roles in proliferation. Oncol Lett 4: 1003-1007, 2012.
17. Liu Y, Zhang X, Li ZJ and Chen XH: Up-regulation of Cx43 expression and GJIC function in acute leukemia bone marrow stromal cells post-chemotherapy. Leuk Res 34: 631-640, 2010.
18. Bruserud Ø, Hovland R, Wergeland L, Huang TS and Gjertsen BT: Fli3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Fli3-ligand effects in AML cell populations with and without genetic Fli3 abnormalities. Haematologica 88: 416-428, 2003.
19. Hatfield KJ, Hovland R, Øyan AM, et al: Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 22: 287-293, 2008.
20. Tsyukunova G, Reikvam H, Hovland R and Bruserud Ø: The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status. Leukemia 26: 557-559, 2012.
21. Balsrud Ø: Effect of dipryridamole, theophylline and verapamil on spontaneous in vitro proliferation of myelogenous leukemia cells. Acta Oncol 31: 53-58, 1992.
22. Dysvik B and Jonassen I: J-Express: exploring gene expression data using Java. Bioinformatics 17: 369-370, 2001.
23. Stavrum AK, Petersen K, Jonassen I and Dysvik B: Analysis of gene-expression data using J-Express. Curr Protoc Bioinformatics Chapter 7: Unit 7.3, 2008.
24. Van Slyke JK and Musil LS: Cytosolic stress reduces degradation of connexin43 internalized from the cell surface and enhances gap junction formation and function. Mol Biol Cell 16: 5247-5257, 2005.
25. Hirabayashi Y, Yoon BI, Tsuboi I, et al: Protective role of connexin 32 in steady-state hematopoiesis, regeneration state, and leukemogenesis. Exp Biol Med 232: 700-712, 2007.
26. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115: 453-474, 2010.
27. Dürig J, Rosenthal C, Halfmeyer K, et al: Intercellular communication between bone marrow stromal cells and CD34+ haematopoietic progenitor cells is mediated by connexin 43-type gap junctions. Br J Haematol 111: 416-425, 2000.
28. Montecino-Rodriguez E, Leathers H and Dorshkind K: Expression of connexin 43 (Cx43) is critical for normal hematopoiesis. Blood 96: 917-924, 2000.
29. Presley CA, Lee AW, Kasil B, et al: Bone marrow connexin-43 expression is critical for hematopoietic regeneration after chemotherapy. Cell Commun Adhes 12: 307-317, 2005.
30. Wong RC, Pébay A, Nguyen LT, Koh KL and Pera MF: Presence of functional gap junctions in human embryonic stem cells. Stem Cells 22: 883-899, 2004.
31. Huettner JE, Lu A, Qu Y, Wu Y, Kim M and McDonald JW: Gap junctions and connexon hemichannels in human embryonic stem cells. Stem Cells 24: 1654-1667, 2006.
32. Wörsdörfer P, Maxeiner S, Markopoulos C, et al: Connexin expression and functional analysis of gap junctional communication in mouse embryonic stem cells. Stem Cells 26: 431-439, 2008.
33. Wong CW, Christen T, Roth I, et al: Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat Med 12: 950-954, 2006.